These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26967277)

  • 1. Communication in Drug Development: "Translating" Scientific Discovery.
    Settleman J; Cohen RL
    Cell; 2016 Mar; 164(6):1101-1104. PubMed ID: 26967277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Precision" drug development?
    Woodcock J
    Clin Pharmacol Ther; 2016 Feb; 99(2):152-4. PubMed ID: 26331240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough drug category demands more communication.
    Carroll J
    Manag Care; 2013 Aug; 22(8):17-8. PubMed ID: 24024248
    [No Abstract]   [Full Text] [Related]  

  • 4. Companies ponder how truly 'personal' medicines can get.
    Baker M
    Nat Med; 2011 May; 17(5):519. PubMed ID: 21546948
    [No Abstract]   [Full Text] [Related]  

  • 5. Reinventing bioinnovation.
    Kaitin KI; Honig PK
    Clin Pharmacol Ther; 2013 Sep; 94(3):279-83. PubMed ID: 23963211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel combination therapies.
    Woodcock J; Griffin JP; Behrman RE
    N Engl J Med; 2011 Mar; 364(11):985-7. PubMed ID: 21323535
    [No Abstract]   [Full Text] [Related]  

  • 7. A forensic analysis of drug targets from 2000 through 2012.
    Munos B
    Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will Precision Medicine Move Us beyond Race?
    Bonham VL; Callier SL; Royal CD
    N Engl J Med; 2016 May; 374(21):2003-5. PubMed ID: 27223144
    [No Abstract]   [Full Text] [Related]  

  • 9. Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development.
    Vicini P; Fields O; Lai E; Litwack ED; Martin AM; Morgan TM; Pacanowski MA; Papaluca M; Perez OD; Ringel MS; Robson M; Sakul H; Vockley J; Zaks T; Dolsten M; Søgaard M
    Clin Pharmacol Ther; 2016 Feb; 99(2):198-207. PubMed ID: 26536838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of original research contributions toward FDA-approved drugs.
    Patridge EV; Gareiss PC; Kinch MS; Hoyer DW
    Drug Discov Today; 2015 Oct; 20(10):1182-7. PubMed ID: 26113307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized medicine's ragged edge.
    Fleck LM
    Hastings Cent Rep; 2010; 40(5):16-8. PubMed ID: 20964159
    [No Abstract]   [Full Text] [Related]  

  • 12. The complexity of integrating speed and safety in drug development and approval.
    Charo RA
    JAMA Intern Med; 2013 Jul; 173(13):1165-6. PubMed ID: 23568604
    [No Abstract]   [Full Text] [Related]  

  • 13. One size does not fit all: Challenging some dogmas and taboos in drug discovery.
    Chai CL; Mátyus P
    Future Med Chem; 2016 Jan; 8(1):29-38. PubMed ID: 26689236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

  • 15. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
    Kesselheim AS; Wang B; Franklin JM; Darrow JJ
    BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent updates and challenges on the regulation of precision medicine: The United States in perspective.
    Chang LC; Colonna TE
    Regul Toxicol Pharmacol; 2018 Jul; 96():41-47. PubMed ID: 29715491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of FDA and EMA drug approval: implications for drug development and cost of care.
    Howie LJ; Hirsch BR; Abernethy AP
    Oncology (Williston Park); 2013 Dec; 27(12):1195, 1198-1200, 1202 passim. PubMed ID: 24624536
    [No Abstract]   [Full Text] [Related]  

  • 18. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug development and FDA approval, 1938-2013.
    Darrow JJ; Kesselheim AS
    N Engl J Med; 2014 Jun; 370(26):e39. PubMed ID: 24963591
    [No Abstract]   [Full Text] [Related]  

  • 20. 10 years into the resurgence of covalent drugs.
    De Vita E
    Future Med Chem; 2021 Jan; 13(2):193-210. PubMed ID: 33275063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.